You are here
Renova Therapeutics, Inc.
http://www.renovatherapeutics.com
UEI: FDV5E79YLFF5
# of Employees: 5
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction
Amount: $805,659.00ABSTRACT Type-1 Diabetes Mellitus (T1DM) affects 1.25 million patients in US with 40,000 new patients annually. Lifespan is shortened 11-13 years, due to kidney and heart disease. Tight glucose contro ...
STTRPhase II2022Department of Health and Human Services National Institutes of Health -
Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction
Amount: $241,698.00ABSTRACT TypeDiabetes MellitusT DMaffectsmillion patients in US withnew patients annuallyLifespan is shortenedyearsdue to kidney and heart diseaseTight glucose control reduces microvascular complicati ...
STTRPhase I2019Department of Health and Human Services National Institutes of Health -
Urocortin Gene Transfer for CHF a Paracrine Approach Using Intravenous AAV
Amount: $1,605,000.00DESCRIPTION provided by applicant Gene transfer for the treatment of cardiovascular diseases is bedeviled by inability to obtain safely and easily sufficient cardiac transgene expression Current ...
STTRPhase II2016Department of Health and Human Services National Institutes of Health -
Urocortin-2 Gene Transfer for CHF: a Paracrine Approach Using Intravenous AAV8
Amount: $240,750.00DESCRIPTION (provided by applicant): Gene transfer for the treatment of cardiovascular diseases is bedeviled by inability to obtain, safely and easily, sufficient cardiac transgene expression. Current ...
STTRPhase I2014Department of Health and Human Services National Institutes of Health
